RecruitingNot ApplicableNCT07272902

Treating Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction: Ablation or Medication

A Randomized Ablation-based Atrial Fibrillation Rhythm Control Versus Rate Control Trial in Patients With Heart Failure and Preserved Ejection Fraction (CABANA-RAFT HF): A Pilot Study


Sponsor

Nova Scotia Health Authority

Enrollment

84 participants

Start Date

Jan 1, 2026

Study Type

INTERVENTIONAL

Conditions

Summary

This study is testing two different ways of treating atrial fibrillation (AF) in people who also have heart failure with mildly reduced or preserved heart function. Patients will randomly be assigned to either rhythm control using catheter ablation or rate control using medicines. The pilot phase will determine if a larger study can be successfully carried out to see which approach better improves survival, reduces hospitalizations, and enhances quality of life.


Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is comparing catheter ablation (a procedure that uses heat or cold to destroy abnormal heart tissue) versus medication alone for treating atrial fibrillation (AFib) in patients who also have a type of heart failure where the heart pumps normally but is stiff (called HFpEF). Both AFib and HFpEF are common together and can worsen each other. **You may be eligible if...** - You are 18 or older - You have atrial fibrillation confirmed by an ECG, Holter monitor, or rhythm strip - You have moderate heart failure symptoms (NYHA class II or III) - Your heart's pumping function is above 40% - You meet specific lab marker thresholds for heart failure (NT-proBNP levels) **You may NOT be eligible if...** - You have had a prior catheter ablation for AFib - Your heart failure is very severe (NYHA class IV) - You have a pacemaker or defibrillator that would interfere with ablation - You have significant valve disease requiring surgery - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

PROCEDURECatheter Ablation for Atrial Fibrillation

Participants randomized to this arm will undergo catheter ablation within 4 weeks of randomization. Pulmonary vein isolation is required; additional ablation strategies may be applied at investigator discretion. Guideline-directed medical therapy for atrial fibrillation and heart failure will also be provided.

DRUGRate Control Medications (beta-blockers, calcium channel blockers, digoxin)

Participants randomized to this arm will receive pharmacologic therapy to achieve guideline-recommended heart rate control (resting HR \<80 bpm, \<110 bpm with exercise). Therapy may include beta-blockers, non-dihydropyridine calcium channel blockers, or digoxin. If adequate control is not achieved with medication, AV nodal ablation and pacing may be used. Guideline-directed medical therapy for atrial fibrillation and heart failure will also be provided.


Locations(1)

QEII HSC

Halifax, Nova Scotia, Canada

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07272902


Related Trials